Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8566 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD8566 | DRUG | Single 6 mg oral solution dose |
| AZD8566 IV carbon labelled | DRUG | Single 10 mcg intravenous carbon-14 microtracer dose |
| Placebo | DRUG | 10ml oral solution administered once a day over 10 days. |
Inclusion Criteria: * Provision of written informed consent * Clinically normal physical findings and laboratory values as judged by the investigator with normal ECG * Females who are permanently or surgically sterile or post-menopausal and males Exclusion Criteria: * History of any convulsions o...
AZD8566 is an investigational small molecule being developed by AstraZeneca PLC (AZN). It has been studied in healthy volunteers in Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics. The drug is not approved and remains in clinical development.
AZD8566 has been studied in healthy volunteer studies to assess its safety, tolerability, and pharmacokinetics. It has not been evaluated in any patient population or for any specific disease indication in the available clinical trials.
AZD8566 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca sponsored the Phase 1 clinical trials of AZD8566.
AZD8566 is in Phase 1 clinical development. All completed trials for AZD8566 were Phase 1 studies conducted in healthy volunteers. The drug is investigational and has not received regulatory approval.
AZD8566 has been studied in three completed Phase 1 trials: NCT00749333, a single ascending dose study; NCT00844103, a multiple ascending dose study; and NCT00866385, a food effect and microtracer study. All trials were conducted in the United Kingdom with healthy volunteers.
AZD8566 is not FDA approved. It is an investigational drug that has only been studied in Phase 1 clinical trials in healthy volunteers. These trials were designed to assess safety, tolerability, and pharmacokinetics, not to support an approval application.